Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Clinical Cardiology

Diabetes

Clinical Pharma

Coronary

CAD Pharma

Presentation

ACC 2025

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

Presentation ACC 2025

Presenter: Roland R. Van Kimmenade

March 30, 2025